Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients

Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients

Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely...

Full description

Bibliographic Details
Main Authors: Muttia Amalia, Meidi Utami Puteri, Fadlina Chany Saputri, Rani Sauriasari, Bambang Widyantoro
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Life
Subjects:
atherosclerosis
antiplatelet
glycoprotein-Ib (GP1b)
platelet
type 2 diabetes mellitus (T2DM)
Online Access:https://www.mdpi.com/2075-1729/13/7/1473

Internet

https://www.mdpi.com/2075-1729/13/7/1473

Similar Items